Business
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused on Patients (n=12) Treated with Phase 2 Regimen67% Overall Response Rate (ORR) and 58% Complete Response (CR) RateFive Patients (42%) Maintained a CR at Month 6; Four of Five CRs (80%) Ongoing Beyond Six Months, Including Two at 30+ Months and One at 24+ Months Clinical Safety and Immune Recovery Comparable to Autologous TherapiesRobust AlloCAR T Cell Expansion and Persistence Documented in Responding PatientsAllogeneic CAR T Treatment Initiated at a Median of Three Days After Enrollment Without Need for Leukapheresis or Bridging Therapy; 100% Received Allogeneic CAR T Product Candidates Meeting Manufacturing SpecificationsEnrollment in Potentially Pivotal Phase 2 ALPHA2 Trial Ongoing with Expected Completion 1H2024 SOUTH SAN FRANCISCO, Calif., June 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented long-term follow up data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. These data will also be presented in a poster session at the European Hematology Association (EHA) Hybrid Congress on June 9, 2023. “We are excited to be the first to demonstrate the potential of allogeneic CD19 CAR T to induce durable complete remissions at a rate similar to approved autologous CD19 CAR T therapies. Our Phase 2 regimen also had a safety profile, including immune recovery, in line with approved options,” said Zachary Roberts, M.D., Ph.D., Executive Vice President, Research & Development and Chief Medical Officer. “We believe our AlloCAR T product candidates have the potential to break down widespread access barriers to CAR T, and ultimately establish a new paradigm in cell therapy. These data underlie the excitement we and investigators have for our ongoing potentially pivotal Phase 2 ALPHA2 trial.” The updated analysis of ALPHA/ALPHA2 examined data from 12 CAR T-naïve patients with r/r LBCL who received a single dose of ALL...